Vanda Pharmaceuticals Inc. - 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed on December 2, 2013, by Vanda Pharmaceuticals Inc., a Delaware corporation. The report details executive compensation decisions made by the Compensation Committee of the Board of Directors regarding 2013 performance bonuses, 2014 salary adjustments, and new equity incentive awards.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation figures:
- 2013 Bonuses Awarded: Total of $671,563 distributed to three named executive officers.
- 2014 Base Salaries: Approved annual salaries range from $360,000 to $580,000.
- 2014 Target Bonuses: Set at 40% to 60% of the respective 2014 base salaries.
- Equity Grants: Options and Restricted Stock Units (RSUs) granted at an exercise price of $11.59 per share.
Material Changes
This report does not disclose material changes to the company's financial position or operations compared to prior periods. It serves as a notification of specific personnel compensation actions approved on December 2, 2013.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on business outlook, or discussion of risks and contingencies. The Compensation Committee noted that executive compensation was benchmarked against a peer group analysis conducted by Towers Watson.
Investor Verification Checklist
- Verify the total number of shares underlying the new option grants (270,000 total) and RSU awards (90,000 total).
- Confirm the vesting schedules: Options vest monthly over four years; RSUs vest annually starting January 1, 2015.
- Review the 2006 Equity Incentive Plan terms to understand dilution implications.
- Check subsequent filings for the actual payout of the 2013 bonuses and the realization of 2014 performance targets.